



# Retraction Note: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

Mohammad Ebrahim Parsanezhad<sup>1,2</sup> · Saeed Alborzi<sup>1</sup> · Bahia Namavar Jahromi<sup>1</sup>

Published online: 23 December 2023  
© Springer-Verlag GmbH Germany, part of Springer Nature 2023

## Retraction Note to:

*Arch Gynecol Obstet* (2004) 269:125–129  
<https://doi.org/10.1007/s00404-002-0437-x>

The Editor-in Chief has retracted this article because it has been published previously [1]. All authors agree with this retraction.

## Reference

1. Parsanezhad ME, Alborzi S, Jahromi BN (2002) A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. *Int J Fertil Womens Med* 47(6):272–277

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s00404-002-0437-x>.

---

✉ Mohammad Ebrahim Parsanezhad  
parsame@sums.ac.ir

<sup>1</sup> Department of Obstetrics and Gynecology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>2</sup> Parsanezhad Jenaer Str 41, 28215 Bremen, Germany